Cost-Utility Analysis Hospital Versus Home in Multiple Myeloma
NCT ID: NCT03493737
Last Updated: 2020-08-17
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
43 participants
OBSERVATIONAL
2018-04-10
2020-02-15
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
This study aim to perform a cost-utility analysis of two different strategies in several HaH structures within the Grand Est region in France.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Impacts on Health Outcomes and Resources Utilization of Hospital-at-home for Elderly Patients With Multiple Myeloma
NCT03490084
Cost-Utility Analysis of Home-based Versus Hospital-based Chemotherapy in Multiple Myeloma: Case of Carfilzomib
NCT05184595
The Burden of Multiple Myeloma on Patients and Caregivers Quality of Life: a Canadian Real-World Study
NCT06610045
Neurotoxic Effect of Bortezomib Treatment in Patient With Myeloma Multiple
NCT02976272
Quality of Life of Non-transplant Candidate Multiple Myeloma Patients Treated With Early Bortezomib
NCT01060202
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
This study aim to perform a cost-utility analysis of two different strategies in several HaH structures within the Grand Est region in France: exclusive hospital-based Bortezomib administration versus combined administration in both OH and HaH.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
HaH (Hospital-at-Home)
Bortezomib is injected at Outpatient hospital at day 1 and at Home at further day of cycles
Quality of life surveys
Quality of life surveys by EQ-5D and QLQ-C30
OH (Outpatient Hospital)
Bortezomib is always injected at Outpatient hospital
Quality of life surveys
Quality of life surveys by EQ-5D and QLQ-C30
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Quality of life surveys
Quality of life surveys by EQ-5D and QLQ-C30
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Enrolled in a social security scheme
* Diagnosis of multiple myeloma in first line or relapse
* Treatment plan including Bortezomib, adopted in a multidisciplinary meeting in a department of Hematology in Nancy (main investigator), Reims, Strasbourg University Hospitals or Metz-Thionville and Mulhouse local state-run hospitals
* The patients must have agreed to the treatment protocol and to take IV or PO associated drugs prescribed in addition to Bortezomib
* The patients must meet the 2003 eligibility criteria of the National Agency for Accreditation and Evaluation in Health (ANAES) for chemotherapy at home:
* Absence of severe adaptive or psychological disorders, ability to understand the protocol
* Absence of cognitive impairment
* Availability and agreement of the attending physician
* Home safety and hygiene
* Do not decline to participate in the research and share their personal data
Exclusion Criteria
* Have a follow-up and/or treatment for another condition requiring a particular care during the Bortezomib treatment period
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Central Hospital, Nancy, France
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
CHRU Nancy
Vandœuvre-lès-Nancy, , France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2018-A00103-52
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.